NeuroOne Joins $1 Million NIH-Funded Project to Track Brain Chemistry in Real Time

Key Points

• NeuroOne joined a Dartmouth-led research project to advance neurotransmitter sensing technology for potential use in humans.
• The NIH grant provides approximately $1 million to the research team in its first year—not solely to NeuroOne.
• NeuroOne’s initial share is approximately $200,000 through April 30, 2027, with additional funding expected over the following two years.
• Researchers aim to combine chemical sensing with NeuroOne’s sEEG electrodes to monitor electrical activity and brain chemistry together.
• The announcement describes a research initiative, not a new approved product or completed human clinical study.

NeuroOne Medical Technologies (NASDAQ: NMTC) has entered a research and development subaward agreement with Dartmouth to help develop technology that could measure brain chemistry in real time. The project aims to expand the capabilities of NeuroOne’s electrode platform beyond electrical monitoring by adding neurotransmitter sensing.

Dartmouth Leads Research With NIH BRAIN Initiative Funding

Dartmouth Associate Professor of Engineering Hui Fang is leading the project, which received approximately $1 million in first-year funding from the National Institute of Neurological Disorders and Stroke through the NIH BRAIN Initiative.

The research brings together Dartmouth, the VA Medical Center, Beth Israel Deaconess Medical Center and NeuroOne. Additional funding is expected during the next two years, although the announcement does not specify those future amounts.

NeuroOne Will Receive About $200,000 for Initial Development Work

Under its agreement with Dartmouth, NeuroOne will receive approximately $200,000 through April 30, 2027. The company also expects additional funds over the following two years.

That distinction matters: the $1 million award supports the broader research team, while NeuroOne receives a portion through its subaward. The announcement does not provide a detailed budget or schedule for the company’s development work.

Sensors Aim to Measure Brain Chemistry Alongside Electrical Activity

The project seeks to combine advanced chemical sensing with NeuroOne’s sEEG electrodes. The goal is to give physicians and researchers tools that can track both electrical activity and neurochemical signaling in real time.

Measuring both could help researchers better understand neurological and psychiatric disorders and potentially support future diagnostic and treatment approaches. However, the technology is being advanced toward potential human use; the announcement does not report completed human testing or demonstrated patient benefits.

Investor Takeaway: Funded Research Expands the Platform’s Potential

For NMTC investors, the agreement provides funded development work and a collaboration that could broaden the applications of NeuroOne’s thin-film electrode technology. Management sees the project as an opportunity to build on its platform’s recording, stimulation and therapeutic uses.

The commercial impact remains uncertain. The announcement does not identify a product-launch date, regulatory pathway or sales forecast. The next meaningful evidence will be whether the team can successfully integrate chemical sensing into the electrodes and demonstrate its usefulness for human applications.